Bicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of “Buy” by Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received a consensus rating of “Buy” from the eight research firms that are currently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $41.20.

Several analysts have recently weighed in on BCAX shares. RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. HC Wainwright boosted their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Rodman & Renshaw began coverage on Bicara Therapeutics in a report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a report on Wednesday, February 12th.

Bicara Therapeutics Stock Performance

BCAX stock opened at $13.82 on Friday. The business’s 50 day moving average is $14.49. Bicara Therapeutics has a twelve month low of $11.10 and a twelve month high of $28.09.

Institutional Trading of Bicara Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Spire Wealth Management acquired a new stake in shares of Bicara Therapeutics during the 4th quarter worth about $31,000. BNP Paribas Financial Markets purchased a new position in shares of Bicara Therapeutics during the fourth quarter valued at approximately $32,000. Legal & General Group Plc acquired a new stake in Bicara Therapeutics during the fourth quarter worth approximately $33,000. Summit Investment Advisors Inc. purchased a new stake in Bicara Therapeutics in the 4th quarter worth approximately $35,000. Finally, Virtus ETF Advisers LLC acquired a new position in Bicara Therapeutics in the 4th quarter valued at $69,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.